Ionis Pharmaceuticals (ISI) Financial Statements
Ionis Pharmaceuticals Financial Overview
Ionis Pharmaceuticals's market cap is currently $6.45B. The company's EPS TTM is $-3.46; its P/E ratio is -12.58; Ionis Pharmaceuticals is estimated to report earnings on November 4, 2026, and the estimated EPS forecast is $-1.09. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 944.00M | $ 705.14M | $ 787.65M | $ 587.37M | $ 810.46M |
| Gross Profit | $ 928.00M | $ 693.92M | $ 778.51M | $ 573.25M | $ 799.61M |
| Operating Income | $ -382.00M | $ -475.08M | $ -353.73M | $ -410.19M | $ -30.19M |
| EBITDA | $ -284.31M | $ -353.72M | $ -235.87M | $ -227.76M | $ -5.19M |
| Net Income | $ -381.00M | $ -453.90M | $ -366.29M | $ -269.72M | $ -28.60M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 2.68B | $ 2.30B | $ 2.33B | $ 2.00B | $ 2.13B |
| Total Assets | $ 3.52B | $ 3.00B | $ 2.99B | $ 2.53B | $ 2.61B |
| Total Debt | $ 2.61B | $ 1.42B | $ 1.45B | $ 1.37B | $ 1.25B |
| Net Debt | $ 2.24B | $ 1.17B | $ 1.05B | $ 1.09B | $ 381.86M |
| Total Liabilities | $ 3.03B | $ 2.42B | $ 2.60B | $ 1.96B | $ 1.84B |
| Stockholders' Equity | $ 489.09M | $ 588.35M | $ 386.69M | $ 572.89M | $ 771.74M |
| Cash Flow | |||||
| Free Cash Flow | $ -320.03M | $ -546.23M | $ -335.52M | $ -294.47M | $ 12.90M |
| Operating Cash Flow | $ -268.58M | $ -500.95M | $ -307.51M | $ -274.37M | $ 30.80M |
| Investing Cash Flow | $ -277.78M | $ -134.03M | $ -214.13M | $ -262.64M | $ 194.91M |
| Financing Cash Flow | $ 675.84M | $ 478.06M | $ 644.08M | $ -55.30M | $ 245.93M |
Currency in USD